Month: September 2026

NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) — Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) today announced that its Board of Directors (the “Board”) declared the Fund’s monthly distributions for October, November and December 2026.

Q4 2026 Distribution Schedule

Month	Record Date	Ex-Dividend Date	Payable Date	Amount per Share
October 2026	October 9, 2026	October 9, 2026	October 23, 2026	$0.1180
November 2026	November 12, 2026	November 12, 2026	November 27, 2026	$0.1180
December 2026	December 10, 2026	December 10, 2026	December 24, 2026	$0.1180

Shares purchased on or after the applicable ex-distribution dates will not receive the distributions discussed above. Distributions may include net investment income, capital gains and/or return of capital. Any portion of the Fund’s distributions that is a return of capital does not necessarily reflect the Fund’s investment performance and should not be confused with “yield” or “income.” The Fund’s Section 19a-1 Notice, if applicable, contains additional distribution composition information and may be obtained by visiting https://privatewealth.brookfield.com/fund/brookfield-real-assets-income-fund-inc. The tax status of distributions will be determined at the end of the taxable year. Based on current estimates, it is anticipated that a portion of the distributions paid in calendar year 2026 will be treated for U.S. federal income tax purposes as a return of capital. The final determination of the tax status of those 2026 distributions will be made in early 2027 and provided to stockholders on Form 1099-DIV. Please contact your financial advisor with any questions.

Brookfield Real Assets Income Fund Inc. is managed by Brookfield Public Securities Group LLC. The Fund uses its website as a channel of distribution of material information about the Fund. Financial and other material information regarding the Fund is routinely posted on and accessible at https://privatewealth.brookfield.com/fund/brookfield-real-assets-income-fund-inc

Media enquiries
Rachel Wood:  E rachel.wood@brookfield.com  |  T (212) 613-3490
Investor Relations:  E privatewealth@brookfield.com  |  T (855) 777-8001

Investing involves risk; principal loss is possible. Past performance is not a guarantee of future results.
Brookfield Real Assets Income Fund Inc. is distributed by Foreside Fund Services, LLC.

SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, the Company received a notice (the “Notice”) from the staff of NYSE American LLC (the “NYSE American”) that the Company was not in compliance with the NYSE American’s continued listing standards in Part 10, Section 1003(a)(ii)of the NYSE American Company Guide (the “Company Guide”)requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice also indicates that the Company is not currently eligible for any exemption in Section 1003(a) of the Company Guide (including the exemption provided for companies with total value of market capitalization exceeding $50 million among other things).

In connection with its non-compliance with Section 1003(a)(ii), the Company must submit a plan (the “Plan”) to the NYSE American by October 21, 2026, advising of actions it has taken or will take to regain compliance with the continued listing standards by March 21, 2028. If the NYSE American determines to accept the Plan, the Company will be notified in writing and will be subject to periodic reviews, including quarterly monitoring for compliance with the Plan. If the Company does not submit a plan or if the Plan is not accepted, NYSE American will commence delisting proceedings. Furthermore, if the Plan is accepted but the Company is not in compliance with the continued listing standards by March 21, 2028, or if the Company does not make progress consistent with the Plan, the NYSE American will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.

The Notice has no immediate effect on the listing or trading of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and the Common Stock will continue to trade on the NYSE American under the symbol “CLDI”, but will have an added designation of “.BC” to indicate the status of the common stock are “below compliance.” The Notice does not affect the Company’s ongoing business operations or its reporting requirements with the U.S. Securities and Exchange Commission.

The Company’s management is reviewing its options to address the deficiencies and expects to submit a compliance plan on or before the deadline set by the NYSE American.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The Company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.

CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets metastatic non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.

Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here.

Forward-Looking Statements

This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding Calidi’s intention to submit a plan to regain compliance with NYSE American’s continued listing standards, NYSE American’s acceptance of any such plan, and Calidi’s ability to regain compliance by March 21, 2028. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that NYSE American does not accept Calidi’s compliance plan; the risk that Calidi is unable to regain compliance with NYSE American’s continued listing standards by March 21, 2028, or to make progress consistent with its plan during the plan period; the risk that NYSE American commences delisting proceedings, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials or to increase its stockholders’ equity; and, risks related to changes in applicable laws or regulations; manufacturing and supply chain matters; the availability of capital and other resources; and changes in business, market, economic or competitive conditions. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s annual report filed with the SEC on Form 10-K on March 27, 2026, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Investors Contact:
IR@calidibio.com

Media Contact:
PR@calidibio.com

EDMONTON, Alberta, Sept. 25, 2026 (GLOBE NEWSWIRE) — Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, today announces the change of its Chief Executive Officer (CEO). Effective November 23, 2026, Dr. Madi Madiyalakan will be retiring from his position as Quest’s CEO. Dr. Madiyalakan has been the CEO of Quest since August 2006. Mr. Jeffrey Shon, a director of Quest, will be taking over the role of CEO. Mr. Shon has considerable experience in the areas of legal, regulatory and corporate affairs, including venture capital funding focused on emerging technologies.

J. Mark Lievonen, Chairman of Quest’s Board, stated, “We thank Dr. Madiyalakan for his tireless efforts, hard work and unwavering loyalty to Quest over the past 20 years, and we wish him all the best in his future endeavors. We welcome Mr. Shon, as CEO of Quest following Dr. Madiyalakan’s retirement, and wish him success in his efforts to run the Company and create shareholder value.”

Quest also announces that it will hold its annual and general shareholder meeting (AGM) on Monday, November 23, 2026, at 3:00 pm in the Company’s corporate offices in Edmonton. Dr. Madiyalakan will not be standing for re-election as a director at the AGM but will continue to consult to Quest as required to ensure continuity of its business operations.

About Quest PharmaTech Inc.

Quest PharmaTech Inc is a publicly traded, Canadian based biopharmaceutical company (QPT: TSX-V) developing products to improve the quality of life. The Company has a 26.6% ownership interest in a Korean company called OQPBIOM Inc., a private company that owns the immunotherapy assets and is developing immunotherapeutic products for the treatment of cancer. Quest also has a 23% ownership interest in OncoVent, a Chinese joint venture developing antibody-based immunotherapeutic products for cancer for the Greater China territory. Quest is also developing proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer which is currently in late preclinical stage. To learn more, visit www.questpharmatech.com. 

Forward Looking Statements  

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen. The forward-looking information contained herein is made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation, the risk factors that can be found in the Company’s securities law filings which have been filed under the Company’s SEDAR+ profile at www.sedarplus.ca. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

For further information:
Dr. Madi R. Madiyalakan, CEO, Quest PharmaTech Inc.
Tel: (780) 448-1400,
E-mail: madi@questpharmatech.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

San Francisco, CA, Sept. 25, 2026 (GLOBE NEWSWIRE) — Future Money Acquisition Corporation (Nasdaq: FMAC) (the “Company”) announced today that on September 22, 2026, the Company received a deficiency letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because it has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2026 (the “Form 10-Q”), the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission.

The Notice states that the Company has 60 calendar days from the date of the Notice, or until November 23, 2026, to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) (the “Plan”). If Nasdaq accepts the Plan, Nasdaq may grant the Company an exception of up to 180 calendar days from the Form 10-Q filing due date, or until March 22, 2027, to regain compliance. If Nasdaq does not accept the Plan, the Company will have the opportunity to appeal that determination to a Nasdaq Hearings Panel.

The Company is working diligently to complete and file the Form 10-Q as soon as practicable. The Company intends to take all necessary steps to regain compliance with the Nasdaq Listing Rules. However, there can be no assurance that the Company will take the steps necessary to regain compliance within the required period, that the Plan will be accepted by Nasdaq, that the Company will be granted an exception, or that the Company will be able to meet the conditions of any exception or the continued listing requirements during any compliance period that may be granted.

Future Money Acquisition Corporation

The Company is a blank check company newly incorporated as a Cayman Islands exempted company with limited liability for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, including those with respect to the anticipated timing for filing the Form 10-Q and the Company’s ability to regain compliance with Nasdaq’s listing rules, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements, including risks related to the completion of the Company’s interim financial statements and related interim review, the Company’s ability to file the Form 10-Q within the anticipated timeframe, the Company’s ability to regain and maintain compliance with Nasdaq’s continued listing requirements, and those set forth in the Risk Factors section of the Company’s registration statement and final prospectus for the Company’s initial public offering filed with the SEC. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law. Investors should not place undue reliance on the Company’s forward-looking statements.

Contact Information:

Future Money Acquisition Corporation
Siyu Li
steven.li@fumoac.com 

BOSTON, MA, Sept. 25, 2026 (GLOBE NEWSWIRE) — Netcapital Inc. (Nasdaq: NCPL) (the “Company”) today announced that on September 21, 2026, it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2026, and remains delinquent in filing its Annual Report on Form 10-K for the fiscal year ended April 30, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). That rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.

As previously announced on August 27, 2026, the Company received an earlier notice from Nasdaq on August 24, 2026 regarding the delinquent Form 10-K. Under that notice, the Company has until October 23, 2026 to submit a plan to regain compliance covering both delinquent reports. If Nasdaq accepts the plan, it may grant the Company an exception of up to 180 calendar days from the original due date of the Form 10-K, or until February 9, 2027, to regain compliance. If Nasdaq does not accept the plan, the Company may appeal to a Nasdaq Hearings Panel.

The notice has no immediate effect on the listing or trading of the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol “NCPL.”

The Company intends to submit its compliance plan within the required timeframe and to file the Form 10-K and Form 10-Q as soon as practicable. There can be no assurance that Nasdaq will accept the plan or that the Company will regain compliance within any exception period granted.

About Netcapital Inc.

Netcapital Inc. is a fintech company with a scalable technology platform that allows private companies to raise capital online and provides private equity investment opportunities to investors. The Company’s consulting group, Netcapital Advisors, provides marketing and strategic advice and takes equity positions in select companies. The Company’s funding portal, Netcapital Funding Portal, Inc., is registered with the U.S. Securities and Exchange Commission and is a member of the Financial Industry Regulatory Authority. The Company’s broker-dealer, Netcapital Securities Inc., is also registered with the SEC and is a member of FINRA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plan to regain compliance with Nasdaq’s listing rules and the timing of its periodic filings. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including the Company’s ability to complete the audit and review of its financial statements, the availability of financing, Nasdaq’s acceptance of the Company’s plan, and other risks described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements, except as required by law.

Contact:
800-460-0815 
ir@netcapital.com

Zug, Switzerland, September 25, 2026 – WISeKey International Holding Ltd (“WISeKey” or the “Company”) (SIX: WIHN; NASDAQ: WKEY) today announced that it expects the previously announced redomiciliation of WISeKey from Switzerland to the British Virgin Islands to become effective on October 2, 2026 (the “Redomiciliation”). The Redomiciliation is being implemented through the cross-border merger of WISeKey with and into its wholly owned British Virgin Islands subsidiary, WISeQey Corp. (formerly known as WISeKey International Corp., “WISeQey”), with WISeQey continuing as the surviving company (the “Merger”). The Merger and Redomiciliation are expected to become legally effective on October 2, 2026, following completion of the applicable registration procedures.

Upon the effectiveness of the Merger:

• WISeKey will be absorbed into WISeQey and WISeKey will cease to exist as a separate legal entity; and
• WISeQey will succeed to all of the assets, rights, liabilities and obligations of WISeKey;

The Redomiciliation is not expected to change WISeKey’s underlying businesses or operations. The WISeQey’s operational headquarters and place of effective management will remain in Switzerland, and its global operations will continue as before.

In connection with the expected completion of the Merger, the ordinary shares of WISeQey are expected to commence trading on the Nasdaq Global Market under the ticker symbol “WQEY” and on the SIX Swiss Exchange, where they will have a primary listing, under the ticker symbol “WQEY”, on or about October 5, 2026.

We expect October 2, 2026 to be the last day of trading for the existing American Depositary Shares of WISeKey on Nasdaq and for the existing Class B shares of WISeKey on SIX Swiss Exchange. Following delisting and cancellation, holders of WISeKey securities will receive the applicable securities of WISeQey in accordance with the exchange ratios, elections and settlement procedures previously communicated to shareholders and described in the prospectus relating to the Merger, with the first day of trading for the WISeQey ordinary shares expected to occur on October 5, 2026.

WISeKey shareholders approved the Merger and the related Merger Agreement at the Extraordinary General Meeting held on September 9, 2026.

Carlos Moreira, Founder, Chairman and CEO of WISeKey, said: “The completion of our redomiciliation marks an important milestone in the evolution of WISeKey. It also marks the transition from WISeKey to WISeQey, a new name that symbolizes our strategic expansion into the quantum-security era. For 27 years, WISeKey has built its expertise around cybersecurity, digital identity, trusted semiconductors and secure communications. WISeQey represents the extension of that experience into the quantum world, with quantum security becoming an increasingly important pillar across our technologies and investments. The ‘Q’ in WISeQey reflects this evolution. Our objective is to combine nearly three decades of cybersecurity expertise with post-quantum cryptography, quantum technologies, secure semiconductors, trusted AI and satellite-based secure communications to help build the next generation of digital trust infrastructure. With WISeQey’s redomiciliation to the British Virgin Islands, we believe the new corporate structure will provide greater flexibility to support our continued international development and access to global capital markets, while maintaining our operational headquarters, effective management and roots in Switzerland.
This is therefore more than a change of domicile and corporate name. It represents the next chapter of WISeKey: building on the 27-year heritage of WISeKey while expanding our mission from securing today’s digital world to securing the emerging quantum world. We would like to thank our shareholders, employees, partners and advisors for their continued support throughout this transformation.”

About WISeKey
WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeID, which specializes in RoT and PKI solutions for secure authentication and identification in IoT, blockchain, and AI, (iii) WISeSat AG, which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) WISe.ART Corp, which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, and (v) SEALCOIN AG, which focuses on decentralized physical internet with DePIN technology and houses the development of the SEALCOIN platform.

Each subsidiary contributes to WISeKey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

Press and investor contacts:

WISeKey International Holding Ltd  Company Contact:  Carlos Moreira Chairman & CEO Tel: +41 22 594 30 00 info@wisekey.com

WISeKey Investor Relations (US)  Contact:  Lena Cati The Equity Group Inc. Tel: +1 212 836-9611 lena.cati@theequitygroup.com

Disclaimer:
This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”) or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.

Important Additional Information and Where to Find It
In connection with the merger, WISeQey filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form F-4 (File No. 333-297507), which was declared effective on July 31, 2026 and includes a prospectus of WISeQey . INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE MERGER. The registration statement, prospectus, and other documents filed by WISeKey or WISeQey with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov or by directing a request to WISeKey International Holding Ltd, General-Guisan-Strasse 6, 6300 Zug, Switzerland.

Participants in the Solicitation
WISeKey, WISeQey, and their respective directors and executive officers may be deemed to have been participants in the solicitation of proxies from WISeKey’s shareholders in connection with the merger. Information regarding the interests of these directors and executive officers in the merger is included in the prospectus. Additional information regarding WISeKey’s directors and executive officers is also included in WISeKey’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025, filed with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov.

No Offer or Solicitation
This communication is for informational purposes only and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Forward-looking statements are typically identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “should,” “would,” “could,” “may,” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding: the anticipated benefits of the redomiciliation and merger; the expected timing and completion of the merger and the effectiveness thereof; the satisfaction of remaining conditions to the merger, including regulatory approvals; and the expected listing of WISeQey shares on Nasdaq and SIX Swiss Exchange.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which WISeKey and WISeQey operate, and management’s beliefs and assumptions. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Important factors that could cause actual results to differ materially from forward-looking statements include, but are not limited to: the risk that the merger may not be completed in a timely manner or at all; failure to satisfy remaining closing conditions; failure to obtain required regulatory approvals, including from Nasdaq, SIX Swiss Exchange, or the Swiss Takeover Board; the risk that the anticipated benefits of the redomiciliation may not be realized; changes in applicable laws or regulations; general economic and market conditions; and other risks and uncertainties described in WISeKey’s filings with the SEC, including its Annual Report on Form 20-F. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this communication. WISeKey does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.